DUBLIN, Ireland & MALVERN, PA — Mallinckrodt plc and Endo, Inc. (OTCQX: NDOI) have detailed the senior leadership structure for their anticipated merger, a move aimed at creating a global leader in branded specialty pharmaceuticals and generics and sterile injectables (GxSI). The merger, announced earlier this year, is projected to close by the second half of 2025, subject to shareholder approval and customary conditions. It also includes a phase to spin off the GxSI business into an independent entity.
“As we combine two companies with a rich legacy of innovation, we are building a highly capable and balanced team of proven leaders to help create a promising new future,” said Siggi Olafsson, who is currently President and CEO of Mallinckrodt and will assume the same role in the merged organization.
Leadership Team Highlights
The newly combined company will feature a senior leadership team drawn from both organizations, reflecting deep institutional expertise and a focus on innovation. Included in the leadership lineup are:
- Tracy Basso, Chief Human Resources Officer, Endo
- Mark Bradley, transitioning to Chief Integration Officer from his current CFO role at Endo
- Lisa French, Chief Commercial Officer, Mallinckrodt
- Henriette Nielsen, Chief Transformation Officer, Mallinckrodt
- Paul O’Neill, Quality & Operations, Specialty Brands, Mallinckrodt
- Cheryl Stouch, Chief Information Officer, Endo
- Mark Tyndall, Chief Legal Officer & Corporate Secretary, Mallinckrodt
- Susan Williamson, Chief Compliance Officer, Endo
Recruitment efforts are ongoing for key roles, including Chief Financial Officer and heads of Business Development & Strategy, as well as Research & Development. The merged company will also debut a new name soon after the merger concludes, signaling its renewed focus on branded specialty pharmaceuticals.
Introducing Par Health
The GxSI segment, to be spun off after the merger, will operate under the name Par Health, which builds on over 40 years of Par Pharmaceutical’s history as a leader in the generics market. Until the separation is complete, Par Health will function as a segment of the merged entity.
Stephen Welch, currently leading Specialty Generics at Mallinckrodt, is slated to become President and CEO of Par Health upon the spin-off. During the interim period, he will report directly to Olafsson.
This strategic move spotlights Mallinckrodt and Endo’s efforts to improve patient care while enhancing operational focus. Once complete, the merger will position both entities to address evolving pharmaceutical needs with greater agility and expertise.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.